Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4Observational 3

Sponsor

Cancer Type

Dermatologic 4Gastrointestinal 1

Conditions

Breast Neoplasms 2400Neoplasms 1819Carcinoma, Non-Small-Cell Lung 1599Prostatic Neoplasms 1298Colorectal Neoplasms 1140Lung Neoplasms 984Neoplasm Metastasis 830Multiple Myeloma 792Leukemia, Myeloid, Acute 767Ovarian Neoplasms 674Pancreatic Neoplasms 662Melanoma 660Squamous Cell Carcinoma of Head and Neck 586Carcinoma, Hepatocellular 567Recurrence 562Brain Neoplasms 527Glioblastoma 513Head and Neck Neoplasms 500Stomach Neoplasms 497Triple Negative Breast Neoplasms 465Lymphoma 454Uterine Cervical Neoplasms 450Carcinoma, Renal Cell 425Precursor Cell Lymphoblastic Leukemia-Lymphoma 410Lymphoma, Non-Hodgkin 389Endometrial Neoplasms 381Sarcoma 368Lymphoma, Follicular 356Urinary Bladder Neoplasms 354Hematologic Neoplasms 352

Interventions

folfirinox 1Taxes 1Risk Factors 1Oxaliplatin 1Leucovorin 1Irinotecan 1HhAntag691 1Gemcitabine 1Fluorouracil 1Erlotinib Hydrochloride 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Basal Cell × 1 year × Clear all
NCT00833417 2026-05-11

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

Genentech, Inc.

Phase 2 Completed
104 enrolled 13 charts
Dermatologic

Carcinoma, Basal Cell, Neoplasms, Basal Cell

NCT06483555 2026-04-23

PANGEA

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
104 enrolled
DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

NCT06398418 2025-09-04

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

Rise Therapeutics LLC

Phase 1 Recruiting
33 enrolled
Dermatologic

Adenoma, Melanoma, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡